YAP1 and lung carcinoma: We confirmed both in vitro and in vivo that YAP1/WWTR1/TEAD-dependent transcription is acutely activated following osimertinib treatment in EGFR mutant lung cancer and pharmacologic and genetic ablation of this complex strongly suppresses persister cells.